Author: Editor

Dr. Mark Kris, MD or Memorial Sloan Kettering discuss the role of BRAF mutations in NSCLC and the potential treatment with BRAF and MEK inhibitors.

Dr. Mark Kris, MD of Memorial Sloan Kettering discusses the Lung Cancer Mutation Consortium and the role of Next Generation Sequencing in NSCLC.

At the European Society for Medical Oncology (ESMO) 2014 Congress, Dr Eleni Efstathiou (The University of Texas MD Anderson Cancer Center, Houston, TX) discusses prospective management strategies for prostate cancer. Topics of interest include radiotherapy, androgen-deprivation therapy (ADT), inhibitors of nuclear export and androgen-signalling inhibitors. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof. Dr. med. Peter Fasching (Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany) summarises the status of poly (ADP-ribose) polymerase (PARP) inhibitors in preclinical and clinical development for the treatment of breast cancer. Prof. Dr. med. Fasching explains the design of the EMBRACA study, which is a 2:1 randomised phase 3 study comparing the efficacy and safety of the PARP inhibitor, talazoparib, versus physician’s choice in patients with locally advanced and/or metastatic BRCA-related breast cancer. This programme is supported by BioMarin Pharmaceutical European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof. Dr. med. Michael Untch (HELIOS Klinikum Berlin-Buch, Berlin, Germany) and Prof. Dr. med. Peter Fasching (Friedrich-Alexander-Universitä?t Erlangen-Nürnberg, Erlangen, Germany) discuss the functions of the BRCA1 and BRCA2 proteins in response to DNA damage in BRCA-related breast cancer. The development of molecular profiling in BRCA-related breast cancer has allowed an increasingly accurate assessment of tumour biology and should allow us to utilise this mutation in the treatment of the cancer. This programme is supported by BioMarin Pharmaceutical European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Catherine Kelly (Mater Misericordiae University Hospital, Dublin, Ireland) reviews what is known about the functions of poly (ADP-ribose) polymerase (PARP) and outlines the rational development of PARP inhibitors as anticancer agents for tumours associated with BRCA gene mutations. Dr Kelly focuses on the phase 3 EMBRACA study, which is evaluating the PARP inhibitor, talazoparib, versus physician’s choice in patients with locally advanced and/or metastatic BRCA-related breast cancer. This programme is supported by BioMarin Pharmaceutical European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof. Dr. med. Peter Fasching (Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany) describes targeting the defect in DNA repair in BRCA-related breast cancer with poly (ADP-ribose) polymerase (PARP) inhibitors. In BRCA-related breast cancer cells, DNA double-strand break repair is impaired, so inhibition of PARP, which has a role in DNA single-strand break repair, increases the susceptibility for additional DNA damage and cell death. Accordingly, PARP inhibitors may be important novel therapeutic agents for the treatment of BRCA-related breast cancer. This programme is supported by BioMarin Pharmaceutical European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews…

Michael Kolodziej, MD, National Medical Director, Oncology Strategies, Aetna, Inc. talks about Next Steps in Oncology Payment Reform for Established Provider & Payer Teams

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof. Dr. med. Michael Untch (HELIOS Klinikum Berlin-Buch, Berlin, Germany) and Prof. Dr. med. Peter Fasching (Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany) discuss the clinical development of the poly (ADP-ribose) polymerase (PARP) inhibitor, talazoparib, for the treatment of BRCA-related breast cancer. The ongoing EMBRACA study is a 2:1 phase 3 study comparing the efficacy and safety of the PARP inhibitor, talazoparib, versus physician’s choice in patients with locally advanced and/or metastatic BRCA-related breast cancer. This programme is supported by BioMarin Pharmaceutical European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Roberta L. Buell, Principal, OnPoint Oncology, LLC discusses the Top 2015 Reimbursement Issues & ICD-10 Update from the Coding Mistress

Robert Baird Jr., RN, MSA, Chief Executive Officer, Dayton Physicians Network discusses Payment Reform for Established Provider & Payer Teams

David Eagle discusses what Are the Key Cost Drivers of Cancer Care moving forward at the COA meeting in Orlando

At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Catherine Kelly (Mater Misericordiae University Hospital, Dublin, Ireland) reviews the medical and social implications of BRCA gene mutation testing. Women with a deleterious BRCA gene mutation can be offered various management options, including prophylactic surgery and chemoprevention, to reduce the risk of breast cancer development. It is important for clinicians to understand and respond to a patients subjective experience during the clinical management process. This programme is supported by BioMarin Pharmaceutical European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

James W. Hodge, PhD, MBA, Investigator, Laboratory of Tumor Immunology & Biology, Center for Cancer Research, National Cancer Center talks about Perspective from the NCI: Importance of Immunotherapy Trials

Phil Johnson, MS, RPh, Director of Pharmacy (Retired), Moffitt Cancer Center talks about Biosimilar Overview: Opportunities & Issues

Jeff Mortier talks about the latest information about the Cancer Payment Reform Bill.

At the Myeloma 2015 meeting, Prof Kenneth Anderson (Harvard Medical School, Boston, MA) chairs a discussion with Prof Jesús San Miguel (University of Salamanca, Salamanca, Spain) and Prof Antonio Palumbo (University of Torino, Torino, Italy) on immunotherapies that are in clinical development for the treatment of multiple myeloma. Novel immune-based combinations that seem particularly noteworthy are discussed. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the Myeloma 2015 meeting, Dr Keith Stewart (Mayo Clinic, Scottsdale, AZ) chairs a discussion with Prof Gareth Morgan (University of Arkansas, Fayetteville, AR) and Prof Leif Bergsagel (Mayo Clinic, Scottsdale, AZ) on studies involving new tumour biology-guided strategies for treating multiple myeloma (MM). They focus on immune modulators and inhibitors of critical signalling pathways in MM. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Matti Aapro (Clinique de Genolier, Genolier, Switzerland) discusses the design and rationale of the Multidisciplinary Application of Genomics in Clinical Practice (MAGIC) survey. The MAGIC survey is an evaluation of the heterogeneity of the treatment decisions made by clinicians regarding the need for adjuvant chemotherapy in breast cancer patients. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Person they are interveiwng, their credentials

Bobbi Buell from onPoint Oncology talks about ICD-10 and what it means to oncology payments

Keith L. Knutson, PhD, Director, Cancer Vaccines and Immune Therapies Program, Vaccine & Gene Therapy Institute of Florida Practical Immuno-Oncology 101 for Oncologists & Nurses

Laura Stevens, Program Director for CMMI Come Home Project talks about the Come Home Project and how it works.

Ricky Newton of COA talks about the new COPA program called Community Oncology Pharmacy Association at the COA annual meeting in Orlando, FL.

Ted Okon and Peter Yu, MD discuss new legislative issues associated with oncology for 2015 at the COA annual meeting in Orlando, FL.

Bo Gamble & Carol Murtaugh talk about What does it take to become a Oncology Medical Home at the annual Community Oncology Alliance meeting in Orlando, 2015

On the first day of the Myeloma 2015 meeting, Dr Keith Stewart (Mayo Clinic, Scottsdale, AZ) chairs a discussion with Prof Jesús San Miguel (University of Salamanca, Salamanca, Spain) and Prof Antonio Palumbo (University of Torino, Torino, Italy) on new approaches for treating multiple myeloma (MM). Topics include early intervention for smoldering MM, treatment strategies for high-risk MM, and novel drugs in clinical development that may improve patient outcomes in MM. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Dr Clifford Hudis (Memorial Sloan Kettering Cancer Center, New York, NY) discusses the opportunities at the 14th St. Gallen International Breast Cancer Conference 2015 to develop new guidelines in breast cancer treatment. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Véronique Diéras (Institut Curie, Paris, France) discusses the phase 2 PALOMA-1 study of the cyclin-dependent kinase 4/6 inhibitor, palbociclib, in combination with letrozole versus letrozole alone as first-line treatment for women with oestrogen receptor-positive (ER+), HER2-negative (HER2-), advanced breast cancer. The addition of palbociclib to letrozole significantly improved progression-free survival in this patient population. A phase 3 trial is in progress. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Kidney Cancer Organization Welcome Lyon Meeting 2015 Carolyn Konosky

Kidney Cancer Meeting Lyon, France 2015: Immunotherapy versus targeted treatments in metastatic renal cell carcinoma:The return game? Sylvie NEGRIER MD, PhD Centre Léon Bérard, Lyon Université Lyon I

Kidney Cancer Meeting Lyon, France 2015: Functional imaging in renal cancer: a 10 year history. Tom Powles Barts Cancer Institute ECMC, UCH and Royal Free Hospitals: London Cancer Queen Mary University of London

Kidney Cancer Meeting Lyon, France 2015: Treatment beyond second line Camillo Porta Medical Oncology, I.R.C.C.S. San Matteo University Hospital Foundation, Pavia, Italy

Kidney Cancer Meeting Lyon, France 2015: Will Immunotherapy Marginalise Targeted Therapy to a Salvage Role by 2020? Tim Eisen University of Cambridge

Kidney Cancer Meeting Lyon, France 2015: Have Results of Recent Randomized Trials Changed the Role of mTOR Inhibitors? Bernard Escudier Institut Gustave Roussy Villejuif, France

Kidney Cancer Meeting Lyon, France 2015: What Have Sequencing Trials Taught Us?

Kidney Cancer Meeting Lyon, France 2015: Role of SBRT in the management of lung and liver metastases Ronan TANGUY, M.D. Radiation Oncologist

Kidney Cancer Meeting Lyon, France 2015: New target:FGFR & c-MET Laurence Albiges Gustave Roussy Institute, Dana-Farber Cancer Institute

Kidney Cancer Meeting Lyon, France 2015: 1st line treatment:what has changed in the last 2 years? Martin Gore PhD FRCP Royal Marsden Hospital Institute of Cancer Research London

Kidney Cancer Meeting Lyon, France 2015: LOCAL TREATMENT FOR LUNG ET LIVER METASTASES SURGERY/ABLATION IS THE GOLD STANDARD – Alain Ravaud, MD PhD Bordeaux University Hospital, Bordeaux, France

Kidney Cancer Meeting Lyon, France 2015: Toxicity from Checkpoint Inhibitors James LarkinFRCP PhD

Kidney Cancer Meeting Lyon, France 2015: TKI drug interaction: what else do I need to know for my patient for anti-VEGF? Romano Danesi, MD, PhD Professor of Pharmacology Department of Clinical and Experimental Medicine University of Pisa Medical School, Italy

Kidney Cancer Meeting Lyon, France 2015: Mechanisms and management of hypertension associated with anti-VEGF-treatment Stephane Ederhy Service de Cardiologie Hopital Saint Antoine Paris, France

Kidney Cancer Meeting Lyon, France 2015: Skin Side Effects Associated with Kidney Cancer Treatment Christiane Thallinger, MD University of Vienna, Department of Oncology, General Hospital vienna

Kidney Cancer Meeting Lyon, France 2015: Vaccines for RCC: Rationale and Clinical Update Hans Hammers M.D. / Ph.D. Assistant Professor: Medical Oncology, Chemical Therapeutics Johns Hopkins Kimmel Cancer Center

Kidney Cancer Meeting Lyon, France 2015: New Targets to Reverse VEGF Resistance Prof. Eric Raymond, MD, PhD Head of Medical Oncology UNIL-CHUV Lausanne – Switzerland

Kidney Cancer Meeting Lyon, France 2015: T-Cell Checkpoints in RCC:Musings from a non-immunologist Primo N. Lara, Jr., M.D. Professor of Medicine University of California Davis School of Medicine Associate Director for Translational Research UC Davis Comprehensive Cancer Center Sacramento, CA, USA

Kidney Cancer Meeting Lyon, France 2015: Is renal cryoablation becoming an effective alternative to partial nephrectomy? J GARNON

Kidney Cancer Meeting Lyon, France 2015: Medical Oncologist and Urologist Different Views on Cytoreductive Nephrectomy? The Oncologists view Viktor Grünwald

Kidney Cancer Meeting Lyon, France 2015:Have Medical Oncologist and Urologist Different Views on Cytoreductive Nephrectomy? Axel Bex, The Netherlands Cancer Institute Amsterdam, The Netherlands

Kidney Cancer Meeting Lyon, France 2015: Should we push for even more minimal invasive and conservative approaches in kidney cancer? The view of the medical oncologist. Manuela Schmidinger, Medical University of Vienna Austria

Kidney Cancer Meeting Lyon, France 2015: Should we push even more for minimal invasive and conservative approaches in kidney cancer? Antonio Alcaraz Hospital Clínic Barcelona

Kidney Cancer Meeting Lyon, France 2015: Should We Now Biopsy Every Single Renal Tumor Before Treating? Bernard Escudier Institut Gustave Roussy Villejuif, France

Kidney Cancer Meeting Lyon, France 2015: SHOULD WE NOW BIOPSY EVERY SINGLE RENAL TUMOR BEFORE TREATING ? Alessandro VOLPE, M.D. University of Eastern Piedmont – Maggiore della Carità Hospital Novara, Italy

Kidney Cancer Meeting Lyon, France 2015: John Fitzpatrick Tribute: Life in the Fast Lane

Kidney Cancer Meeting Lyon, France 2015: Immunotherapy for Kidney Cancer: Finally Center-Stage? Nizar M. Tannir, MD, FACP Professor and Deputy Chair GU Medical Oncology, MD Anderson

Kidney Cancer Meeting Lyon, France 2015: Clinical Relevance of Cancer Gene, James Brugarolas M.D., Ph.D. Kidney Cancer Program Leader Virginia Murchison Linthicum Endowed Scholar Associate Professor of Internal Medicine & Developmental Biology University of Texas Southwestern Medical Center

Kidney Cancer Meeting Lyon, France 2015: Tribute to Pieter De Mulder by Hein Van Poppel Professor and Chairman UZ Leuven Adjunct Secretary General EAU. Nephron Sparing SurgeryPast, Present and Future

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof Peter Schmid (Barts Cancer Institute, London, UK) discusses the key challenges in the manufacture, development and approval of biosimilars for breast cancer treatment. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Dr Matti Aapro (Clinique de Genolier, Genolier, Switzerland) discusses his highlights from the 14th St. Gallen International Breast Cancer Conference 2015. In addition, he provides an update on the novel combination antiemetic, netupitant and palonosetron (NEPA), for the prevention of chemotherapy-induced nausea and vomiting, and prospective opportunities and challenges for managing breast cancers with a focus on adjuvant therapies. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof Geoff Lindeman (The Walter and Eliza Hall Institute of Medical Research, Victoria, Australia) discusses the importance of the new therapeutic targets of BCL-2, BH3 mimetics, in oestrogen receptor-positive (ER+) breast cancer, including the challenges in the development process and use in clinical practice. Preclinical models of ER+ breast cancer demonstrate that BH3 mimetics combined with tamoxifen improves the effectiveness of hormone therapy. Clinical studies of the BH3 mimetic, ABT-199, are beginning in ER+ breast cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof Paul Declerck (KU Leuven, Leuven, Belgium) discusses the understanding of the current state of the biosimilar market as well as future challenges of the development and regulation of biosimilars. Biosimilars, which are biological products that demonstrate no clinically meaningful differences to an approved biological product, are currently approved in several areas of the world, and the biosimilars development pipeline is relatively large.European Medical JournalWebsite: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

This is my interview with Jeri Francoeur, Breast Cancer Patient Advocate, breast cancer survivor, and President of the Susan G Komen Chapter in Central Florida.

At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Richard Finn (UCLA, Los Angeles, CA) discusses the development of the cyclin-dependent kinases (CDKs) 4 and 6 inhibitor, palbociclib, for breast cancer treatment. The phase 2 PALOMA-1 trial showed that the addition of palbociclib to letrozole significantly increased the progression-free survival versus letrozole alone in oestrogen receptor-positive, HER2-negative metastatic breast cancer. Subsequently, palbociclib received accelerated approval as frontline treatment for this patient population. Current trials are investigating palbociclib in other areas of breast cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference (SG-BCC) 2015, Dr Clifford Hudis (Memorial Sloan Kettering Cancer Center, New York, NY) discusses how mining big data can complement research approaches and improve patient care in cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Dr John Bartlett (Ontario Institute for Cancer Research, Toronto, Canada) discusses his study on the influence of cut points in the proliferation marker, Ki67, for clinical decision making in breast cancer patients, and suggests that Ki67 could be used as a continuous marker in this setting. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof Sibylle Loibl (German Breast Group, Neu-Isenburg, Germany) discusses recent advances in neoadjuvant therapy for breast cancer, including the rationale for the use of the surrogate endpoint for survival, pathological complete response (pCR), in neoadjuvant studies. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof Giuseppe Viale (European Institute of Oncology and University of Milan, Milan, Italy) discusses the opportunities and challenges of developing new agents for breast cancer treatment, including optimising the use of drugs that target genetically defined breast cancer and the integration of these approaches. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Clifford Hudis (Memorial Sloan Kettering Cancer Center, New York, NY) discusses the use of electronic medical records as a source of ‘big data’ that could potentially transform healthcare. CancerLinQ is one initiative that is aiming to aggregate and analyse data collected from patients. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jia Ruan (Weill Cornell Medical College, New York, NY) discusses the clinical relevance of a phase II study of the biologic doublet of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma. Part 1: http://www.oncologytube.com/v/1034706/dr-jia-ruan-at-ash-2014-phase-ii-study-of-lenalidomide-plus-rituximab-as-initial-treatment-for-mantle-cell-lymphoma Part 2: http://www.oncologytube.com/v/1034707/dr-jia-ruan-at-ash-2014-phase-ii-study-of-lenalidomide-plus-rituximab-as-initial-treatment-for-mantle-cell-lymphoma This programme has been supported by sponsorship from Celgene European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jia Ruan (Weill Cornell Medical College, New York, NY) discusses a phase II study of the biologic doublet of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma, including the trial design, efficacy and safety endpoints, and results. Part 1: http://www.oncologytube.com/v/1034706/dr-jia-ruan-at-ash-2014-phase-ii-study-of-lenalidomide-plus-rituximab-as-initial-treatment-for-mantle-cell-lymphoma Part 2: http://www.oncologytube.com/v/1034707/dr-jia-ruan-at-ash-2014-phase-ii-study-of-lenalidomide-plus-rituximab-as-initial-treatment-for-mantle-cell-lymphoma This programme has been supported by sponsorship from Celgene European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Immunotherapy Forum Video #28: Doctors are still weighing the pros and cons of giving a cancer patient immunotherapy before or after resection surgery. In part 1 of 2 videos, Dr. Jason Luke details those risks and benefits.

At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Clifford Hudis (Memorial Sloan Kettering Cancer Center, New York, NY) discusses how prospective randomised trials in breast cancer treatment can adapt to the modern healthcare landscape. There is a promising potential for electronic medical records to provide data that is complementary to randomised trials, thereby improving research approaches in cancer treatment. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof John Gribben (Barts Cancer Institute, London, UK) and Prof Marek Trn?ný (Charles University Hospital, Prague, Czech Republic) discuss recent advances in the management of patients with mantle cell lymphoma, including maintenance treatment and the development of personalised medicine. Part 1: http://www.oncologytube.com/v/1034690/ash-2014-prof-john-gribben-and-prof-marek-trn-n-discuss-recent-advances-in-mantle-cell-lymphoma-treatment Part 2: http://www.oncologytube.com/v/1034691/ash-2014-prof-john-gribben-and-prof-marek-trn-n-discuss-recent-advances-in-mantle-cell-lymphoma-treatment This programme has been supported by sponsorship from Celgene European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof John Gribben (Barts Cancer Institute, London, UK) and Prof Marek Trn?ný (Charles University Hospital, Prague, Czech Republic) discuss novel therapies and the future of chemotherapy-based regimens for the management of patients with relapsed or refractory mantle cell lymphoma. Part 1: http://www.oncologytube.com/v/1034690/ash-2014-prof-john-gribben-and-prof-marek-trn-n-discuss-recent-advances-in-mantle-cell-lymphoma-treatment Part 2: http://www.oncologytube.com/v/1034691/ash-2014-prof-john-gribben-and-prof-marek-trn-n-discuss-recent-advances-in-mantle-cell-lymphoma-treatment This programme has been supported by sponsorship from Celgene European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

What should be the protocol for a rising PSA in an undiagnosed patient? Dr. Geo Espinosa of NYU-Langone Medical Center lays out the desired pathway in the context of patient-centric holistic uro-oncology.

Dr Giuseppe Curigliano (European Institute of Oncology, Milan, Italy) provides an overview of immune approaches for the treatment of breast cancer at the 14th St. Gallen International Breast Cancer Conference 2015, including: The prognostic influence of tumour-infiltrating lymphocytes; Ongoing clinical trials of targeted therapies that modulate the immune system the PD-1 inhibitor, pembrolizumab, for triple-negative breast cancer, and the combination of trastuzumab and PD1-inhibitor for HER2-positive breast cancer; Tumour antigen cancer vaccines and ductal carcinoma in situ (DCIS). European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Giuseppe Viale (European Institute of Oncology and University of Milan, Milan, Italy) discusses personalised genomic medicine for breast cancer, including the challenges of designing meaningful clinical trials to identify novel and relevant genetic disease biomarkers and the requirement for collaboration by multidisciplinary teams. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Dr. Geo Espinosa of NYU-Langone Medical Center explains the concept of Integrative Urology – the union of traditional and complementary standards of care to provide a more holistic, patient-centric modality.

Dr. Lluis Cecchini of the Hospital del Mar in Barcelona talks about the necessity for patients to become more involved in the management of their disease.

The European Board of Urology recently certified the Urology Department of the Hospital del Mar in Barcelona as a urological training center. Dr. Albert Frances explains the program elements.

The European Board of Urology recently certified the Urology Department of the Hospital del Mar in Barcelona as a urological training center.

Immunotherapy Forum Video #26: Drs. Jared Weiss and Matthew Hellmann answer questions from the audience following their presentations on immunotherapy for lung cancer. Moderated by Dr. Jack West.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Andrew Davies (University of Southampton, Southampton, UK) discusses a phase II/III study comparing the efficacy and safety of lenalidomide versus investigators choice in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Studies continue to support the clinical relevance of molecularly distinct subtypes of DLBCL. This programme has been supported by sponsorship from Celgene

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Marek Trn?ný (Charles University Hospital, Prague, Czech Republic) discusses the phase 2 SPRINT (MCL-002) study of lenalidomide versus investigators choice in relapsed or refractory mantle cell lymphoma, including the study design; efficacy and safety endpoints; and conclusions. This programme has been supported by sponsorship from Celgene

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Martin Dreyling (Ludwig-Maximilians University of Munich, Munich, Germany) discusses novel biologic therapies for the management of patients with non-Hodgkin lymphoma, including a phase II/III study of lenalidomide versus investigators choice in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

http://cancerGRACE.org/ Immunotherapy Forum Video #24: In Part 1 of 2 videos, Dr. Matthew Hellmann provides an overview of clinical trials currently available to early and late stage lung cancer patients that study single agent immunotherapies (i.e. only one treatment is given).

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jia Ruan (Weill Cornell Medical College, New York, NY) discusses novel therapeutic combinations that are currently being investigated in the clinic to address the unmet need in mantle cell lymphoma treatment. These therapeutic agents include bortezomib, lenalidomide, ibrutinib and rituximab. This programme has been supported by sponsorship from Celgene

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Umberto Vitolo (Città della Salute e della Scienza di Torino, Turin, Italy) discusses novel therapies for mantle cell lymphoma, including biologic approaches with lenalidomide plus rituximab, ibrutinib and ABT-199. This programme has been supported by sponsorship from Celgene

Ted Okon Executive Director of COA conducts an interview with Author Siddhartha Mukherjee, MD and Producer/Director Barak Goodman about the Ken Burns PBS special Cancer:The Emperor of All Maladies. On PBS March 30th, 31st, and April 1st 2015

At the European Society for Medical Oncology (ESMO) 2014 Congress, Prof Charles Swanton (London Research Institute and University College London, UK) discusses how the increased interaction between basic scientists, clinicians and patients is improving cancer medicine.

At the European Society for Medical Oncology (ESMO) 2014 Congress, Prof Charles Swanton (London Research Institute and University College London, UK) discusses TRAcking Cancer Evolution through therapy (TRACERx), which is a study that defines lung cancer in both space and time through multiregion and longitudinal tumour sampling and genetic analysis.

At the European Society for Medical Oncology (ESMO) 2014 Congress, Prof Charles Swanton (London Research Institute and University College London, UK) discusses how we may be able to anticipate tumour evolutionary trajectories for a more proactive approach in clinical practice.

At the European Society for Medical Oncology (ESMO) 2014 Congress, Prof Jonathan Ledermann (University College London, UK) discusses the collaboration between University College London and the Francis Crick Institute that is hoped to increase the interaction between academia and industry.

At the European Society for Medical Oncology (ESMO) 2014 Congress, Prof Charles Swanton (London Research Institute and University College London, UK) discusses the importance of understanding the genetic changes of tumour evolution for the development of more effective management options that are tailored to individual genetic profiles this is termed precision medicine.

At the European Society for Medical Oncology (ESMO) 2014 Congress, Prof Jonathan Ledermann (University College London, UK) discusses recent advances in the management of ovarian cancer, including the use of the poly ADP-ribose polymerase (PARP) inhibitor, olaparib, as maintenance therapy for BRCA-mutated ovarian cancer; anti-angiogenic agents, such as cediranib; and immunomodulatory drugs, such as immune checkpoint inhibitors.

Reports emerging data about molecular subtyping of early-stage breast cancer and patients’ risk of disease recurrence Steven C. Shivers, PhD., Charles E. Cox, MD,

Genomic Profiling, African-American Women and Breast Cancer Risk

Gene Called USP9X and Tamoxifen Resistance

Metastatic Breast Cancer – ER-Positive – Dr. Eitan Amir summarizes the latest updates in ER positive breast cancer from the SABCS meeting in 2014

Biology and Pathology Insights – Dr. John Bartlett presented this session as a summary of the topic from original research presented at the SABCS 2014 session

Dr. John Bartlett Theranostic multiparametric tests improve residual risk assessment in early luminal breast cancer

Dr. Eileen Rakovitch A large prospectively-designed study of the DCIS score: Predicting recurrence risk after local excision for ductal carcinoma in situ patients with and without irradiation – presented at the officially licensed Best of SABCS meeting in Toronto.

Surgical Oncology Highlights summarized from the San Antonio Breast Cancer Symposium sessions, and presented by Dr. Jean-Francois Boileau as part of the licensed Best of SABCS session in Toronto, in January 2015.

Radiation Oncology Highlights – Dr. Eileen Rakovitch summarizing top results from the San Antonio Breast Cancer Symposium

Advances in Early Breast Cancer (Chemotherapy and Targeted Therapy as well as Endocrine Therapy) are discussed by Dr. Maureen Trudeau from Sunnybrook Cancer Centre, Toronto, Canada

Neoadjuvant Treatment of Breast Cancer – A summary of the San Antonio Breast Cancer Symposium 2014, during the OncologyEducation licensed meeting in Canada, presented by Dr. Susan Dent

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Umberto Vitolo (Città della Salute e della Scienza di Torino, Turin, Italy) discusses recent advances in the management of mantle cell lymphoma, including a maintenance approach for young patients and ibrutinib therapy for relapsed patients.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Simon Rule (Derriford Hospital, Plymouth, UK) discusses recent studies of the Bruton’s tyrosine kinase inhibitor, ibrutinib, in mantle cell lymphoma (MCL), including in patients with relapsed or refractory MCL who progress after bortezomib therapy and mutational analysis of these patients with primary resistance to ibrutinib, and ibrutinib in combination with rituximab.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Anton Hagenbeek (Academic Medical Center, Amsterdam, Netherlands) discusses recent investigational advances in chimeric antigen receptor (CAR) T-cell immunotherapy for haematological malignancies, including refractory acute lymphoblastic leukaemia (ALL), chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma (diffuse large B-cell lymphoma, follicular lymphoma).

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof John Gribben (Barts Cancer Institute, London, UK) interviews Prof Peter Hillmen (Leeds General Infirmary, UK) about recent advances in the research of chronic lymphocytic leukaemia (CLL). The understanding of CLL biology is changing how the disease is managed. Prognostic markers help to identify specific patient subgroups and provide insight disease progression in these groups. New studies in drugs, such as ibrutinib, target cell proliferation.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Simon Rule (Derriford Hospital, Plymouth, UK) discusses recent advances in the management of mantle cell lymphoma (MCL), including rituximab maintenance after autologous stem cell transplantation in younger patients, bortezomib (Velcade)-based combinations, and lenalidomide as a single agent and in combination with rituximab (R-squared).

A summary of the new uses of immunotherapy and biomarkers in the treatment of NSCLC by Dr. Nayer Rizvi

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof John Gribben (Barts Cancer Institute, London, UK) interviews Prof Peter Hillmen (Leeds General Infirmary, UK) about recent advances in the research of chronic lymphocytic leukaemia (CLL). Balancing treatment efficacy versus toxicity is important and there is reference to the CLL10 study. Anti-CD1 monoclonal antibody therapy after completing chemotherapy, the 17p deletion, allogeneic transplants and a ‘chemo-free’ approach are also considered.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Christian Gisselbrecht (St. Louis Hospital, Paris, France) discusses recent advances in the management of patients with mantle cell lymphoma (MCL). Rituximab maintenance after autologous haematopoietic stem cell transplantation resulted in prolonged progression-free survival. Ibrutinib is being considered for frontline treatment in MCL.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Robin Foà (Sapienza University, Rome, Italy) discusses how understanding disease biology leads to targeted therapies in different types of leukaemia, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL).

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Rafael Fonseca (Mayo Clinic, Scottsdale, AZ) discusses multiple myeloma and amyloidosis. In multiple myeloma, minimum residual disease (MRD) testing is receiving great interest in the evaluation of treatment and as a prognostic marker. In amyloidosis, proteasome inhibition is emerging as an important novel therapy.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Bertrand Coiffier (Centre Hospitalier Lyon-Sud, Pierre-Benite, France) discusses a phase II trial of interim positron emission tomography (PET) scan-tailored therapy in advanced-stage diffuse large B-cell lymphoma.

Prof Christian Gisselbrecht (St. Louis Hospital, Paris, France) discusses results of recent clinical studies in Hodgkin lymphoma (HL) presented at the 2014 American Society of Hematology (ASH) Annual Meeting, including brentuximab vedotin in combination with other agents, positron emission tomography (PET) for tailored treatment and PD-1 immune checkpoint inhibitors.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Ola Landgren (Memorial Sloane Kettering Cancer Center, New York, NY) discusses the development of therapies with novel monoclonal antibodies in multiple myeloma, including antibodies that target CD38, CS1 and PD-1.

Dr George Follows provides an overview of results of clinical trials in chronic lymphocytic leukaemia (CLL) presented at the 2014 American Society of Hematology (ASH) Annual Meeting. He considers the clinical value of maintenance therapy with anti-CD20 monoclonal antibodies in CLL and molecularly defined subtypes of CLL.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Ian Flinn (Sarah Cannon Cancer Institute, Nashville, TN) discusses the preliminary results of a phase Ib study (GP28331) combining GDC-0199 (ABT-199) and obinutuzumab in patients with relapsed/refractory or previously untreated chronic lymphocytic leukaemia (CLL).

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Bertrand Coiffier (Centre Hospitalier Lyon-Sud, Pierre-Benite, France) discusses the first interim analysis of the phase III prospective Lyma study of rituximab maintenance versus wait and watch after four courses of rituximab, dexamethasone, cytarabine and cisplatin (R-DHAP) followed by autologous stem cell transplantation (ASCT) in previously untreated young patients (under 66 years old) with mantle cell lymphoma.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Christian Gisselbrecht (St. Louis Hospital, Paris, France) discusses the molecular approach in managing diffuse large B-cell lymphoma (DLBCL). The molecularly defined DLBCL subtypes, germinal centre B-cell-like (GCB)-DLBCL and activated B-cell-like (ABC)-DLBCL, have important clinical implications.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Ian Flinn (Sarah Cannon Cancer Institute, Nashville, TN) discusses the selective oral inhibitor of phosphoinositide 3-kinase (PI3K) delta isoform (P110?), idelalisib, in the management of haematological malignancies, including lymphoma and chronic lymphocytic leukaemia (CLL). Idelalisib is considered in combination with other therapies to enhance efficacy endpoints.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Bertrand Coiffier (Centre Hospitalier Lyon-Sud, Pierre-Benite, France) discusses the final analysis of the RO-CHOP phase Ib/II study of the histone deacetylase inhibitor, romidepsin, in association with cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone (CHOP) in previously untreated patients with peripheral T-cell lymphoma.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Anton Hagenbeek (Academic Medical Center, Amsterdam, Netherlands) discusses the investigational approaches of brentuximab vedotin, an anti-CD30 antibody conjugated to a cytostatic microtubule-disrupting agent, in the treatment of previously untreated and refractory/relapse patients with Hodgkin lymphoma.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Ian Flinn (Sarah Cannon Cancer Institute, Nashville, TN) discusses a phase I study of the novel PI3k-?,? inhibitor, duvelisib (IPI-145), in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Dr. Sunil Verma and Dr. Nadia Califaretti discuss case studies in breast cancer.

OncologyEducation.com presents: The CONCORD-2 study aimed to initiate worldwide surveillance of cancer survival by central analysis of population-based registry data, as a metric of the effectiveness of health systems, in order to inform global policy on cancer control.

OncologyEducation.com presents: The CONCORD-2 study aimed to initiate worldwide surveillance of cancer survival by central analysis of population-based registry data, as a metric of the effectiveness of health systems, in order to inform global policy on cancer control.

Armando and Jordan Lastra A Fathers Cancer and a Sons Careerbrought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN)

Rob Rutigliano Testicular Cancer Would be Devastated if NSHOA closed brought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN)

Jeffrey Vacirca, MD – CConquering Cancer Close to Home brought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN)

At the European Society for Medical Oncology (ESMO) 2014 Congress, Dr Susan Galbraith (Vice-President Oncology, AstraZeneca) discusses the National Lung Matrix trial, which is a collaboration between Cancer Research UK, AstraZeneca and Pfizer. This approach aims to improve the interaction between academia and industry, thereby facilitating the development of molecularly defined treatments in lung cancer.

At the European Society for Medical Oncology (ESMO) 2014 Congress, Dr Susan Galbraith (Vice-President Oncology, AstraZeneca) discusses the ongoing phase I/II AURA study of the epidermal growth factor receptor (EGFR) inhibitor, AZD9291, in patients with advanced non-small cell lung cancer (NSCLC) and disease progression while on a previous continuous treatment with an EGFR inhibitor.

At the European Society for Medical Oncology (ESMO) 2014 Congress, Dr Rachel Humphrey (Senior Vice President, Head of Immuno-Oncology, AstraZeneca) discusses the anti-programmed death-ligand 1 (PD-L1) monoclonal antibody, MEDI4736, which is being evaluated in phase I/II studies in patients with various advanced solid tumour types. The combination of MEDI4736 with the anti-cytotoxic T-lymphocyte-associated protein 4 (CTL-4) monoclonal antibody, tremelimumab, is being studied in patients with non-small cell lung cancer.

At the European Society for Medical Oncology (ESMO) 2014 Congress, Dr Susan Galbraith (Vice-President Oncology, AstraZeneca) discusses the Study 19 phase II quality of life study of maintenance treatment with the poly (ADP-ribose) polymerase (PARP) inhibitor, olaparib, in patients with relapsed, high-grade, platinum-sensitive ovarian cancer.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Ola Landgren (Memorial Sloane Kettering Cancer Center, New York, NY) debates the requirement of intense treatment in relapsed multiple myeloma. Dr Landgren refers to results of the phase III ASPIRE study of carfilzomib, lenalidomide and dexamethasone in relapsed multiple myeloma. Although patient outcomes have improved with these new and milder treatments, there is a need to understand patient subgroups that do not response to these treatments.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Philippe Moreau (University Hospital of Nantes, France) discusses novel agents in the management of multiple myeloma. An open-label, multicentre, phase Ib study of the human anti-CD38 monoclonal antibody, daratumumab, in combination with backbone regimens in multiple myeloma, including bortezomib-dexamethasone, bortezomib-thalidomide-dexamethasone, bortezomib-melphalan-prednisone and pomalidomide-dexamethasone, is ongoing. The phase III ASPIRE study showed that addition of carfilzomib to lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed multiple myeloma resulted in a statistically significant improvement in progression-free survival.

Thomas Mccloskey – Non Hodgkins Lymphoma Care Close to Home brought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN)

Yelda Nouri, MD – Cancer Care, an MDs view brought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN)

Rick and Carrie Yanez Husband and Wife Diagnosed With Cancer brought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN)

Dawn Savarese – What does a Chief Revenue Officer do at NSHOA? brought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN)

Ann and Bill An Ovarian Cancer Diagnosis In Sickness and in Health brought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN)

George Calcanes – What does the Chief Clinical Officer do at NSHOA brought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN)

Marie Ships and Merrianne Van Ness Diagnosed with Lung Cancer Received so much Support from NSHOA & her Sister brought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN)

Jeffrey Wong – What does a Pharmacy Techinician do at NSHOA? brought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN)

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Ola Landgren (Memorial Sloane Kettering Cancer Center, New York, NY) discusses the final results from the NCI phase II pilot study of carfilzomib, lenalidomide and dexamethasone in 12 patients with high-risk smouldering multiple myeloma. He assesses the risks and benefits of this therapeutic approach in clinical practice.

Irene Trelfa Clinical Trial Participant: Breast Cancer I feel lucky to be a patient at NSHOA brought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN)

Lynn Fitzpatrick – Nurse Educator North Shore Hematology Oncology brought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN)         north shore hematology oncology, the community oncology alliance (coa), coa, the coa patient advocacy network (cpan), cpan

Humberto Castro – Given Six Months to Live Now Tells Others Not to Give Up brought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN)

Diana Youngs – Everyone the Patient Meets in Community Oncology has Compassion for Patients brought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN)

Prof Paul Richardson (Dana-Farber Cancer Institute, Boston, MA) summarises of results of clinical trials in the management of relapsed or refractory multiple myeloma presented at the 2014 American Society of Hematology (ASH) Annual Meeting. Investigational agents discussed include: proteasome inhibitor, carfilzomib; anti-CD38 monoclonal antibody, daratumumab: anti-SLAMF7 monoclonal antibody, elotuzumab; histone deacetylase (HDAC) inhibitor, panobinostat; HDAC6 inhibitor, ricolinostat; immunomodulatory agent, pomalidomide.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Maria-Victoria Mateos discusses an open-label, multicentre, phase Ib study of the safety, tolerability and dose regimen of the anti-CD38 monoclonal antibody, daratumumab, in combination with backbone regimens in patients with multiple myeloma. Backbone regimens include bortezomib-dexamethasone, bortezomib-thalidomide-dexamethasone, bortezomib-melphalan-prednisone and pomalidomide-dexamethasone.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jeffery Matous ((Colorado Blood Cancer Institute, Denver, CO) discusses the randomised, open-label, multicentre phase III ASPIRE study of carfilzomib, lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jeffery Matous (Colorado Blood Cancer Institute, Denver, CO) discusses combination approaches and novel monoclonal antibodies in multiple myeloma. The phase I MM-008 study is assessing the pharmacokinetics and safety of pomalidomide and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma and renal impairment.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jeffery Matous (Colorado Blood Cancer Institute, Denver, CO) discusses results of recent clinical studies of brentuximab vedotin (BV) in Hodgkin lymphoma (HL). The phase III AETHERA trial is a randomised, double-blind, placebo-controlled study of BV in the treatment of patients at risk of progression following autologous stem cell transplant (ASCT) for HL. A single-arm, two-stage, open-label, phase I/II study is evaluating the safety and efficacy of BV in combination with bendamustine for the treatment of HL in first relapse or refractory patients, prior to ASCT.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Gareth Morgan (University of Arkansas for Medical Sciences, Little Rock, AR; The Institute of Cancer Research, London, UK) discusses high-throughput genetic profiling with an all-molecular diagnostic test for recurrent structural aberrations in multiple myeloma. It is hoped this approach will enable molecular risk-stratified clinical trial design and risk-adapted precision medicine for high-risk patients.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Maria-Victoria Mateos provides an update of a randomised, phase III study, which was initiated in 2007, of lenalidomide plus low-dose dexamethasone versus observation in high-risk smouldering multiple myeloma.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jean-Jacques Kiladjian (Hôpital Saint-Louis & Université Paris Diderot, Paris, France) discusses a post-hoc analysis of the phase III RESPONSE trial, which compared ruxolitinib and best available therapy in patients with polycythaemia vera and splenomegaly who were intolerant of or resistant to hydroxyurea, to determine if treatment outcomes were influenced by baseline spleen volume.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Barbara Eichhorst (University Hospital, Cologne, Germany) discusses the BCL-2 inhibitor, ABT-199, which has shown high efficacy as monotherapy in high-risk chronic lymphocytic leukaemia (CLL) patients. Dose-scheduling modifications address the risk of tumour lysis syndrome. Prospective trials will evaluate ABT-199 in a wider range of CLL patients.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jean-Jacques Kiladjian (Hôpital Saint-Louis & Université Paris Diderot, Paris, France) discusses using a next-generation sequencing approach to assess the mutational patterns of prognostically-relevant mutations (previously identified in myeloproliferative neoplasms) in calreticulin gene-mutated essential thrombocythaemia (ET) patients during interferon alpha (IFN-?) therapy.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Barbara Eichhorst (University Hospital, Cologne, Germany) discusses the final analysis of the international, randomised, phase III CLL10 study. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR) has superior efficacy (higher complete response rates, more minimal residual disease [MRD] negativity, longer progression-free survival) versus bendamustine and rituximab in previously untreated and physically fit patients with advanced chronic lymphocytic leukaemia.

At the Thirteenth International Kidney Cancer Symposium, Dr Sumanta Pal (City of Hope Comprehensive Cancer Center, CA) discusses papillary renal cell carcinoma (pRCC) and a phase 2 clinical trial on the MET inhibitor, volitinib, in patients with pRCC. Although pRCC comprises 1015% of renal cell carcinoma, current understanding and management of this disease is relatively limited. Inappropriate MET activation in cancer cells may be important in pRCC progression. Volitinib is a novel, selective and potent MET inhibitor. Preliminary clinical trials on volitinib in pRCC are promising. This new phase 2 trial aims to further evaluate the efficacy and safety of…

At ESMO 2014, Prof Tom Powles (Barts Cancer Institute, UK) discusses strategies in the management of kidney cancer. Recent clinical trials have increased interest in immunotherapy for kidney cancer. Results from a phase II study investigating the tyrosine kinase inhibitor, cediranib, in VEGF-resistant metastatic kidney cancer suggests a need for improved biomarkers, but developing clinically relevant biomarkers is challenging. Knowledge in the treatment of common kidney cancer subtypes have been applied in the rare papillary renal cell carcinoma subtype.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr David Avigan (Harvard Medical School, Boston, MA) discusses recent investigational advances in the management of multiple myeloma. Novel biological therapies, including proteasome inhibitors and immunomodulatory drugs, have improved patient outcomes, but disease progression remains an issue. An integration of existing approaches, including autologous stem cell transplantation, with newer approaches is recommended. Highlight presentations include topics in anti-CS1 humanized monoclonal antibody, elotuzumab, anti-CD38 monoclonal antibody, daratumumab, PD1-pathway inhibition, tumour vaccines and chimeric antigen receptor (CAR) T-cell immunotherapy.

Prof Claire Harrison (Guys and St Thomas NHS Foundation Trust, London, UK) discusses highlights on myeloproliferative neoplasms (MPNs) from the 2014 American Society of Hematology (ASH) Annual Meeting. A molecular-based approach in MPN studies, which has improved understanding of driver mutations, has rapidly increased recent advances in clinical management. Combinational therapies are in preliminary stages and focus is on the Janus kinase (JAK) inhibitor, ruxolitinib, in combinations that enhance overall patient response. Long-term studies, such as the Evaluation of Xagrid Efficacy and Long-term Safety (EXELS) study, are providing insight in high-risk patients with essential thrombocythemia (ET). Quality of life in…

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Denis-Claude Roy (University of Montreal, Montreal, Canada) discusses a phase II trial that evaluated selective photodepletion of recipient-alloreactive T-cells (ATIR) for haploidentical haematopoietic stem cell transplant in patients with acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). ATIR does not cause any grade III/IV graft-versus-host disease (GvHD) and demonstrates promising treatment-related mortality and overall survival rates.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Keith Stewart (Mayo Clinic, Scottsdale, AZ) discusses recent advances in the treatment of multiple myeloma. The phase III ASPIRE study showed that adding the proteasome inhibitor, carfilzomib, to the standard doublet therapy of lenalidomide and dexamethasone resulted in a higher progression-free survival for relapsed multiple myeloma patients. CD38 represents a promising target for monoclonal antibody-based immunotherapy. Novel anti-CD38 monoclonal antibodies, daratumumab and SAR650984, are undergoing clinical investigation.

Stromal tumor-infiltrating lymphocytes(S-TILs): In the alliance N9831 trial S-TILs are associated with chemotherapy benefit but not associated with trastuzumab benefit

SABCS 2014: ECOG 1199 Trial Commentary by Dr. Sunil Verma: Ten year update of E1199: Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer

SABCS 2014: TNT Trial Commentary by Dr. Sunil Verma: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)

SABCS 2014: SOFT Trial Commentary by Dr. Sunil Verma: Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Analysis of the SOFT trial

The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer Part I results, presented by Dr. Verma

A randomized phase III trial comparing neoadjuvant chemotherapy with weekly nanoparticle-based paclitaxel with solventbased paclitaxel followed by anthracyline/ cyclophosphamide for patients with early breast cancer presented by Dr. Sunil Verma

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Catherine Bollard (Children’s National Medical Center, Washington, DC), Dr Philippe Armand (Dana-Farber Cancer Institute, Boston, MA), Dr Craig Moskowitz (Memorial Sloan Kettering Cancer Center, New York, NY), Dr Nicola Gökbuget (University Hospital Frankfurt, Frankfurt, Germany) and Dr Stephan Grupp (Children’s Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA) answer questions from the press.

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Stephan Grupp (Children’s Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA) presents the results of a study that suggests chimeric antigen receptor (CAR) T cells targeting CD19 (CTL019) can elicit durable remissions in paediatric relapsed or refractory acute lymphocytic leukaemia.

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Joseph Alvarnas (City of Hope National Medical Center, Duarte, CA) presents data from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0803)/AIDS Malignancy Consortium (AMC-071) trial, which prospectively evaluated overall survival after autologous haematopoietic stem cell transplantation in patients with chemotherapy-sensitive, relapsed or refractory HIV-associated lymphoma, including diffuse large B-cell lymphoma, plasmablastic lymphoma, Burkitt/Burkitt-like lymphoma and Hodgkin lymphoma.

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Craig Moskowitz (Memorial Sloan Kettering Cancer Center, New York, NY) presents results from the phase III AETHERA trial, which evaluated the safety and efficacy of brentuximab vedotin in preventing post-autologous stem cell transplant disease recurrence in Hodgkin lymphoma patients.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr David Steensma (Dana-Farber Cancer Institute, Boston, MA), Dr Brent Wood (University of Washington, Seattle, WA), Prof Wendy Stock (University of Chicago Medical Center, Chicago, IL), Dr Christoph Röllig (Universitätsklinikum Dresden, Dresden, Germany), Dr Oliver Ottmann (Goethe-University Hospital, Frankfurt, Germany), Dr Eytan Stein (Memorial Sloan-Kettering Cancer Center, New York, NY) and Prof Farhad Ravandi (The University of Texas MD Anderson Cancer Center, Houston, TX) answer questions from the press.

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Farhad Ravandi (The University of Texas MD Anderson Cancer Center, Houston, TX) discusses the phase III double-blind randomized controlled multinational VALOR study, which evaluated vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first-relapsed or refractory acute myeloid leukaemia.

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Eytan Stein (Memorial Sloan-Kettering Cancer Center, New York, NY) discusses a phase I study of AG-221, an oral, selective, first-in-class, potent inhibitor of the IDH2 mutant metabolic enzyme, in IDH2-mutant acute myeloid leukaemia or pre-leukeamia (including myelodysplastic syndromes, chronic myelomonocytic leukeamia, and myeloproliferative neoplasms).

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Oliver Ottmann (Goethe-University Hospital, Frankfurt, Germany) discusses a Trial of the European Working Group for Adult ALL (EWALL-PH-02), which evaluated nilotinib and chemotherapy for first-line treatment in elderly patients with de novo Philadelphia chromosome/BCR-ABL1-positive acute lymphoblastic leukaemia.

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Christoph Röllig (Universitätsklinikum Dresden, Dresden, Germany) discusses the phase II Study Alliance Leukemia (SAL)-Soraml trial, which evaluated sorafenib versus placebo in addition to standard therapy in younger patients (1860 years old) with newly diagnosed acute myeloid leukaemia.

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Wendy Stock (University of Chicago Medical Center, Chicago, IL) discusses the intergroup trial C10403, which showed that adolescent and young adult patients (1639 years old) with acute lymphoblastic leukaemia (ALL) had better overall and event-free survival with paediatric regimens compared to historical controls.

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Brent Wood (University of Washington, Seattle, WA) discusses the phase III Children’s Oncology Group (COG) study AALL0434, which evaluated a standard 4-drug induction followed by response-based risk stratification, as determined by measured levels of minimal residual disease (MRD), in patients with T-lymphocytic leukaemia. Intermediate and high-risk patients were randomised to receive or not receive additional nelarabine chemotherapy and all patients except those who were low-risk received additional radiation therapy.

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Nicola Gökbuget (University Hospital Frankfurt, Frankfurt, Germany) presents the results of the single-arm phase II study that evaluated the Bispecific T-Cell Engager (BiTE) antibody construct (anti-CD19) blinatumomab in patients with minimal residual disease B-precursor acute lymphoblastic leukaemia.

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Craig Moskowitz (Memorial Sloan Kettering Cancer Center, New York, NY) discusses the preliminary results of a phase Ib study evaluating the PD-1 inhibitor, pembrolizumab, in patients with classical Hodgkin lymphoma after brentuximab vedotin failure.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Brad Kahl (University of Wisconsin School of Medicine, Madison, WI), Dr Craig Moskowitz (Memorial Sloan Kettering Cancer Center, New York, NY), Dr Joseph Alvarnas (City of Hope National Medical Center, Duarte, CA), Prof Keith Stewart (Mayo Clinic, Scottsdale, AZ), Dr María-Victoria Mateos (Hospital Universitario de Salamanca, Salamanca, Spain) and Prof Thomas Martin (University of California San Francisco, San Francisco, CA) answer questions from the press.

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Philippe Armand (Dana-Farber Cancer Institute, Boston, MA) discusses the results of a phase I study evaluating the preliminary efficacy and safety of programmed cell death 1 (PD-1) inhibitor, nivolumab, in patients with relapsed or refractory classical Hodgkin lymphoma.

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Thomas Martin (University of California San Francisco, San Francisco, CA) discusses a phase Ib dose escalation trial of SAR650984 (anti-CD38 monoclonal antibody) in combination with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma.

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr María-Victoria Mateos (Hospital Universitario de Salamanca, Salamanca, Spain) discusses the open-label, multicentre, phase 1b study of daratumumab in combination with standard regimens in patients with multiple myeloma. Standard regimens included bortezomib-dexamethasone, bortezomib-thalidomide-dexamethasone, bortezomib-melphalan-prednisone and pomalidomide-dexamethasone.

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Keith Stewart (Mayo Clinic, Scottsdale, AZ) discusses the randomised, open-label, multicentre phase III ASPIRE study. The results of this study suggest carfilzomib combined with standard multiple myeloma therapy (combination of lenalidomide and dexamethasone) improves treatment responses in patients with relapsed or treatment-resistant multiple myeloma.

Dr Hans Hammers (Johns Hopkins, MD) discusses highlights from the Thirteenth International Kidney Cancer Symposium. Immunotherapies have received significant interest: immune checkpoint inhibitors have the potential to durably control disease. Although significant progress has been made in the clear cell renal cell carcinoma (RCC) subtype, research in therapies for non-clear cell RCC (nccRCC) has been relatively neglected.

At the Thirteenth International Kidney Cancer Symposium, Dr James Brugarolas (University of Texas Southwestern Medical Center, TX) discusses the clinical significance of biologically classifying kidney cancer. Advances in genome sequencing methods allowed the identification of a range of mutations in kidney cancer and accordingly, mutation-defined subtypes. Some mutation-defined subtypes are associated with distinct clinical outcomes and therefore support the use of a molecular classification for treatment decisions. This molecular information may also improve clinical trial design through identification of patients who are more likely to benefit from investigational agents.

At the Thirteenth International Kidney Cancer Symposium, Dr James Hsieh (Memorial Sloan-Kettering Cancer Center, NY) discusses the progress in cancer understanding that has improved clinical management. Advances in technologies, including next-generation sequencing methods, have revolutionised research and clinical approaches.

At the Thirteenth International Kidney Cancer Symposium, Dr James Hsieh (Memorial Sloan-Kettering Cancer Center, NY) discusses the need for clinical trials in non-clear cell renal cell carcinoma (RCC) and new research in papillary RCC (pRCC). Emerging trials in the non-clear cell RCC subtype, pRCC, are hoped to improve the availability of therapies specifically approved for this disease.

At the Thirteenth International Kidney Cancer Symposium, Dr JianJun Gao (The University of Texas MD Anderson Cancer Center, TX) discusses papillary renal cell carcinoma (pRCC) and prospective immunotherapy. pRCC is a relatively uncommon subtype of renal cell carcinoma (RCC) that is distinct from the more common clear cell RCC subtype. It is possible that progress in immunotherapeutic research in clear cell RCC that target common components of the immune system may be clinically applicable for patients with pRCC.

At the Thirteenth International Kidney Cancer Symposium, Dr Abraham Ari Hakimi (Memorial Sloan-Kettering Cancer Center, NY) discusses recent developments in the research of kidney cancer management. Identification of cancer subtypes through molecular profiling may guide future trial design and management options. Combination therapies have the potential to improve efficacy. There are a variety of online resources for patients interested in participating in clinical trials.

At the Thirteenth International Kidney Cancer Symposium, Dr Laurence Albiges (Gustave Roussy, France) provides an overview of papillary renal cell carcinoma (pRCC) and management options for these patients. pRCC comprises 1015% of renal cell carcinoma and specific therapies are not available. There are two clinically distinct types of pRCC. The more common Type 1 pRCC is associated with a mutation in the MET gene.

At the Thirteenth International Kidney Cancer Symposium, Dr Toni Choueiri (Dana-Farber Cancer Institute and Harvard Medical School, MA) discusses the new AstraZeneca-sponsored Phase 2 clinical trial on the c-Met inhibitor, volitinib, in patients with papillary renal cell carcinoma (pRCC). pRCC is the second most common subtype of renal cell carcinoma and is associated with poor clinical outcomes. Dr Choueiri describes how molecular approaches help direct current research in this field and how inappropriate c-Met activation in cancer cells may be important in pRCC progression. Volitinib is a novel c-Met inhibitor; this Phase 2 trial is an open-label, global and multicentre…

At the Thirteenth International Kidney Cancer Symposium, Prof David Kwiatkowski (Brigham and Women’s Hospital, MA) discusses targeting the mTOR pathway in kidney cancer treatment. It may be clinically necessary to target different proteins, mTOR, TSC1 and TSC2, of the mTOR pathway. Mutations in genes encoding for these proteins correlate with therapeutic response, and this may influence clinical trial design and provide the basis for personalised medicine in kidney cancer.

At the Thirteenth International Kidney Cancer Symposium, Dr James Hsieh (Memorial Sloan-Kettering Cancer Center, NY) discusses chromophobe renal cell carcinoma (RCC), which comprises 5% of RCC. Chromophobe RCC variants are important determinants in current treatment options. The incidence of incurable, metastatic disease in chromophobe RCC is 5%. Recent studies have improved the molecular understanding of chromophobe RCC and are hoped to direct therapeutic development.

At the Thirteenth International Kidney Cancer Symposium, Dr JianJun Gao (University of Texas MD Anderson Cancer Center, TX) provides an overview of renal medullary carcinoma (RMC). RMC is a rare and aggressive renal cell carcinoma subtype that primarily occurs in African-American patients with sickle cell trait. Although research in RMC has remained in the preclinical stage, it is hoped that significant progress in more common kidney cancer subtypes will provide applicable data that will improve the management of patients with RMC.

At the Thirteenth International Kidney Cancer Symposium, Dr Hans Hammers (Johns Hopkins, MD) encourages kidney cancer patients to take an active role in health care. Currently, a strategic and patient-tailored approach is recommended in kidney cancer management. Dr Hammers discusses how clinical trials represent opportunities for patients to access new medicines and further therapy development.

At the Thirteenth International Kidney Cancer Symposium, Dr Hans Hammers (Johns Hopkins, MD) discusses the Phase 1 clinical trial that studied the immune checkpoint inhibitors, nivolumab and ipilimumab, in metastatic renal cell carcinoma (mRCC). The primary endpoint was to access safety and tolerability, and the secondary endpoint was to access efficacy. Overall, side effects were manageable and objective response was greater than previously reported with nivolumab monotherapy. These findings directed a subsequent Phase 3 trial.

At the Thirteenth International Kidney Cancer Symposium, Dr Elizabeth Plimack (Fox Chase Cancer Center, PA) discusses highlights from the Thirteenth International Kidney Cancer Symposium. This meeting provides a forum for a varied audience with an interest in renal cell carcionoma (RCC) to exchange information that will help direct future research. The new immunotherapies that target the immune basis of cancer may have clinical applicability in both clear cell and non-clear cell RCC. It is also important to target the unique components of the RCC subtypes. Patients are encouraged to learn about clinical trials and participate if appropriate.

At the Thirteenth International Kidney Cancer Symposium, Dr Elizabeth Plimack (Fox Chase Cancer Center, PA) discusses prospective immunotherapy in kidney cancer management. Newer immunotherapeutic agents have demonstrated efficacy and are expected to be approved for kidney cancer soon. Collaborations between different drug manufactures have facilitated progress in combination therapies.

At the Thirteenth International Kidney Cancer Symposium, Dr Sumanta Pal (City of Hope Comprehensive Cancer Center, CA) discusses his research on stool microbiome. Although in preliminary stages, research in kidney cancer patients suggests that protective bacterial species of the stool microbiome may protect against cancer therapy-induced diarrhoea.

At the Thirteenth International Kidney Cancer Symposium, Dr Toni Choueiri (Dana-Farber Cancer Institute and Harvard Medical School, MA) provides an overview on current strategies in kidney cancer management. Focus in this field is moving away from VEGF and mTOR inhibitors. Current topics of interest include novel targets, acquired mechanisms of therapy resistance and immune checkpoint inhibitors. In lieu of biomarker availability for predicting therapy response, genetic sequencing methods are used to guide research in new combination therapies.

At the Thirteenth International Kidney Cancer Symposium, Dr Abraham Ari Hakimi (Memorial Sloan-Kettering Cancer Center, NY) discusses the current understanding of sarcomatoid renal cell carcinoma (RCC). Sarcomatoid RCC is an aggressive subtype of RCC and presents significant clinical challenges. Modern technologies, including whole-genome sequencing, are hoped to improve the understanding of this disease biology, which ultimately guides treatment and improves disease management.

At the Thirteenth International Kidney Cancer Symposium, Carolyn Konosky (Kidney Cancer Association, IL) encourages kidney cancer patients to have an active role in health care. The Kidney Cancer Association website offers a variety of resources for patients.         thirteenth international kidney cancer symposium, international kidney cancer symposium, kidney cancer patients to have an active role,

At the Thirteenth International Kidney Cancer Symposium, Carolyn Konosky (Kidney Cancer Association, IL) provides an overview of the Kidney Cancer Association, which aims to progress and disseminate understanding of kidney cancer. These meetings provide a forum for different audiences with an interest in kidney cancer to exchange information that contributes to future research.

Latest Lung Cancer Updates from ESMO 2014 – Chemotherapy Advances by Dr. Sunil Verma

Latest Lung Cancer Updates from ESMO 2014 – Advances in ALK Positive NSCLC by Dr. Sunil Verma

Dr. James Brugarolas, M.D., Ph.D. Kidney Cancer Program Leader Associate Professor of Internal Medicine & Developmental Biology University of Texas Southwestern Medical Center discusses RCC Classification at the Kidney Cancer meeting in Chicago

Bernard J. Escudier, M.D. accepts the 2014 Eugene P. Schonfeld Award at the Kidney Cancer meeting in Chicago

Dr. Hiral D. Parekh, M.D. discusses Cost Analysis of an Initial Observation Approach in Metastatic Renal Cell Carcinoma at the Kidney Cancer meeting in Chicago

Dr. Laurence Albiges, M.D., Ph.D. discusses Differential expression of c-MET between primary and metastatic sites in clear cell Renal Cell Carcinomas (ccRCCs) at the Kidney Cancer meeting in Chicago.

Dr. Andre P. Fay, M.D. discusses Whole-Exome Sequencing Predicting Two Extreme Phenotypes of Response to VEGF-targeted Therapies in Patients with Metastatic Clear Cell Renal Cell Carcinoma (mRCC) at the Kidney Cancer meeting in Chicago

Dr. Joshua Lang, M.D., M.S. discusses Development of Pharmacodynamic Biomarkers in Circulating Renal Cancer Cells at the Kidney Cancer meeting in Chicago

Dr. Andrew G. Winer discusses Tumor Purity and Immune Cell Infiltration as a Prognostic Risk Predictor for Clear Cell Renal Cell Carcinoma (ccRCC)

Dr. David Kwiatkowski talks about The mTOR signaling pathwayWho responds to rapalogs and why? at the Kidney Cancer meeting in Chicago.

Dr. Harriet Kluger, M.D.Associate Professor Yale Cancer Center discusses The Met Pathway as a Target in RCC at the Kidney Cancer meeting in Chicago

Dr. David F. McDermott discusses Immune correlates and long-term follow-up of a Phase Ia study of MPDL3280A, an engineered PD-L1 antibody, in patients with metastatic renal cell carcinoma (mRCC) at the Kidney Cancer meeting in Chicago

Dr. Thai Ho, M.D., Ph.D.Mayo Clinic Arizona discusses The Evolving Role of Chromatin and Epigenetics in RCC at the Kidney Cancer meeting in Chicago

Dr. Toni K. Choueiri discusses Risk Factors and a Model to Predict Toxicity-related Treatment Discontinuation in Patients with Metastatic Renal Cell Carcinoma (mRCC) Treated with Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy: Results from the International Metastatic RCC Database Consortium (IMDC)

Dr. Sumanta K. Pal, MD;1 Min Li, PhD;2 Xiwei Wu, PhD;3 Paul Frankel, PhD2   1Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA; 2Department of Biostatistics, City of Hope Comprehensive Cancer Center, Duarte, CA; 3Department of Molecular & Cell Biology, City of Hope Comprehensive Cancer Center, Duarte, CA discusses Bacteriomic profiling reveals potential etiology for vascular endothelial growth factor-tyrosine kinase inhibitor (VEGF-TKI)-related diarrhea in patients with metastatic renal cell carcinoma (mRCC) at the Kidney Cancer meeting in Chicago

Dr. Georg A. BjarnasonDivision of Medical OncologySunnybrook Odette Cancer CentreAssociate Professor, Faculty of Medicine, University of Toronto discusses Dose Reduction or Treatment Interruption Pro: Treatment Interruption and individualized dose/schedule alterationIndividualized Sunitinib as an example? at the Kidney Cancer meeting in Chicago

Dr. David I. Quinn MBBS (Hons) PhD FRACP FACP Associate Professor of Medicine Chief, Section of GU Medical Oncology Division of Medical Oncology Medical Director, Norris Cancer Hospital & Clinics Co-Leader, Developmental Therapeutics Program Member, USC Institute of Urology Kenneth J. Norris Comprehensive Cancer Center Keck School of Medicine University of Southern California discusses Dose Reduction or TreatmentInterruption: Pro Dose Reduction at the Kidney Cancer meeting in Chicago

Dr. Frede Donskov, M.D., PhD Chair, Danish Renal Cancer Group, DARENCA Aarhus University Hospital Denmark discusses Toxicity as a Biomarker at the Kidney Cancer meeting in Chiacgo

Suzanne L. Topalian of Johns Hopkins University School of Medicine Sidney Kimmel Comprehensive Cancer Center discusses Biomarkers for PD-1 checkpoint inhibition at the Kidney Cancer meeting in Chicago

Dr. Drew Pardoll of Johns Hopkins discusses Basic Concepts and Future Horizons in Cancer Immunotherapy at the Kidney Cancer Meeting in Chiacgo

Elizabeth R. Plimack MD MS Director, Genitourinary Clinical Research Associate Professor, Department of Hematology/Oncology discusses Combination immunotherapy + VEGF targeted therapy is the optimal systemic strategy for metastatic RCC at the Kidney Cancer Meeting in Chiacgo

M. Dror Michaelson, MD PhD MGH Cancer CenterBoston, MA discusses how TKIs are the Optimal Front-Line mRCC Treatment

Dr. Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center discusses the Optimal Front-Line Treatment for mRCC

Toni K. Choueiri, MD Clinical Director and Kidney Cancer Center Director The Lank Center for Genitourinary Oncology Dana-Farber Cancer Institute Brigham and Womens Hospital presents Clinical Trials in non-clear cell RCC: ESPN, ASPEN and beyond at the Kidney Cancer Association meeting in Chicago 2014

Ari Hakimi MD Assistant Professor Urologic Oncology Affiliate Department of Computational Biology MSKCC presents Genomic Characterization of Sarcomatoid Clear Cell RCC at the Kidney Cancer Association meeting in Chicago 2014

Jianjun Gao, MD, PhD Department of Genitourinary Oncology MD Anderson Cancer Center presents Molecular Characterization of Renal Medullary Carcinoma at the Kidney Cancer Association meeting in Chicago 2014

Gabriel G. Malouf, MD, PhD Assistant professor Department of medical oncology Pitié-Salpêtrière Hospital, Paris, France discusses Translocation Renal Cell Carcinomas: Molecular insights and Future Directions at the Kidney Cancer Association meeting in Chiacgo 2014

Laurence Albiges, MD, PhD Lank Center for Genitourinary Oncology presents Papillary Renal Cell Carcinoma at the Kidney Cancer Association meeting in Chicago 2014

James Hsieh MD PhD MSKCC Translational Kidney Cancer Research Program (TKCRP) presents13thIKCS Chicago Rare Kidney Cancer:Chromophobe RCC at the Kidney Cancer Association meeting in Chicago 2014

Michael L. Blute Sr. MD Chief Urology MGH Walter S. Kerr Jr. Professor of Surgery Harvard Medical School presents Case Presentations Kidney Cancer Association meeting in Chicago 2014

Michael L. Blute Jr of MD Anderson presents the Recurrence After Surgery in Non-metastatic RCC with Thrombus; Risk Factors From A Contemporary Multicenter Analysis at the Kidney Cancer Association meeting in Chicago 2014

Stephen H. Culp, M.D., Ph.D. Assistant Professor, Department of Urology discusses Cytoreductive Nephrectomy at the Kidney Cancer Association meeting in Chicago 2014

Sarah P. Psutka MD Fellow in Urologic Oncology Mayo Clinic, Rochester, MN presents the Latest On IVC Tumor Thrombus at the Kidney Cancer Association meeting in Chicago 2014

Jonathan Coleman, MD Memorial Sloan-Kettering Cancer Center Weill – Cornell University Medical College presents Kidney Cancer Management:The Role of Lymph Node Dissection at the Kidney Cancer Association meeting in Chicago 2014

At the iwNHL 2014, Prof Francesco D’Amore (Aarhus University, Aarhus, Denmark) interviews Dr Elaine Jaffe (National Cancer Institute, Maryland, USA) and Prof Laurence de Leval (IUP Institut universitaire de pathologie, Lausanne, Switzerland) about their involvement at this workshop. Dr Jaffe describes the important abnormal contribution of B-cell proliferation in angioimmunoblastic T-cell lymphoma and other T-cell lymphomas of follicular T-helper cell derivation. As a result, a neoplastic precursor cell is speculated. Prof de Leval describes recent sequencing discoveries in peripheral T-cell lymphomas that have provided new insight in tumour understanding.

Thomas D. Atwell, MD presents Ablation of larger and recurrent tumors at the Kidney Cancer Association meeting in Chicago 2014